ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial

Momelotinib (MMB) is a JAK1/2 and ACVR1 inhibitor with demonstrated clinical activity in all 3 hallmarks of myelofibrosis (MF): anemia, constitutional symptoms, and splenomegaly. In this phase 2 open-label translational biology study (NCT02515630) of 41 transfusion-dependent patients with MF, we exp...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Main Authors: Oh, Stephen T., Talpaz, Moshe, Gerds, Aaron T., Gupta, Vikas, Verstovsek, Srdan, Mesa, Ruben, Miller, Carole B., Rivera, Candido E., Fleischman, Angela G., Goel, Swati, Heaney, Mark L., O’Connell, Casey, Arcasoy, Murat O., Zhang, Yafeng, Kawashima, Jun, Ganz, Tomas, Kowalski, Mark, Brachmann, Carrie Baker
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7509854/
https://ncbi.nlm.nih.gov/pubmed/32915978
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002662
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares